Equillium, Inc. (NASDAQ:EQ) Shares Purchased by DCF Advisers LLC

DCF Advisers LLC raised its stake in shares of Equillium, Inc. (NASDAQ:EQ) by 91.0% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 62,947 shares of the company’s stock after buying an additional 29,985 shares during the period. DCF Advisers LLC owned approximately 0.18% of Equillium worth $47,000 as of its most recent SEC filing.

Equillium Trading Down 1.2 %

Equillium stock opened at $0.80 on Friday. The stock has a market cap of $28.34 million, a price-to-earnings ratio of -5.71 and a beta of 1.87. The company’s 50-day moving average price is $0.76 and its two-hundred day moving average price is $0.81. Equillium, Inc. has a 52 week low of $0.49 and a 52 week high of $2.99.

Equillium Profile

Equillium, Inc, a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis.